1477 Results

People

  1. Motzer
    Motzer
  2. Hudis
    Hudis
  3. Aghajanian
    Aghajanian
  4. O'Reilly
    O'Reilly
  5. Kris
    Kris
  6. Scher
    Scher
  7. Panageas
    Panageas
  8. Saltz
    Saltz
  9. Schwartz
    Schwartz
  10. Kelsen
    Kelsen

Groups

  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)
  7. Epidemiology and Biostatistics (194)
  8. Biostatistics Service (169)
  9. Gastrointestinal Oncology Service (160)
  10. Population Sciences Research Program (158)
  1. "fatigue"
Formats
  1. Journal Article (1402)
  2. Review (38)
  3. Research Letter (13)
  4. Editorial (10)
  5. Conference Paper (5)
  6. Guidelines (4)
  7. Correspondence (3)
  8. Book Section (2)
Groups
  1. Department of Medicine (1039)
  2. Solid Tumor Oncology Division (784)
  3. Hematologic Malignancies, Division of (287)
  4. Survivorship Research (234)
  5. Center for Hematologic Malignancies (216)
  6. Genitourinary Oncology Service (208)

More Groups

People
  1. Robert Motzer (85)
  2. Clifford Hudis (49)
  3. Carol Aghajanian (46)
  4. Eileen O'Reilly (46)
  5. Howard Scher (44)
  6. Mark Kris (44)

More People

Years
  1. 2025 (60)
  2. 2024 (132)
  3. 2023 (89)
  4. 2022 (46)
  5. 2021 (33)
  6. 2020 (85)

More Years

Publications
  1. Journal of Clinical Oncology (108)
  2. Clinical Cancer Research (82)
  3. Cancer (63)
  4. Lancet Oncology (50)
  5. Gynecologic Oncology (41)
  6. Annals of Oncology (37)

More Publications

Publishers
  1. Elsevier Inc. (244)
  2. Springer (133)
  3. American Society of Clinical Oncology (114)
  4. Elsevier Science, Inc. (108)
  5. Oxford University Press (101)
  6. American Association for Cancer Research (89)

More Publishers

Results (1477)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): Final analysis of a randomised, open-label, phase 3 study
    Journal Article

    Diaz, L. A. Jr; Shiu, K. K.; Kim, T. W.; Jensen, B. V.; Jensen, L. H.; Punt, C.; Smith, D.; Garcia-Carbonero, R.; Benavides, M.; Gibbs, P.; more...
    Lancet Oncology (2022)

    Fulltext@MSK | Save
  • Crimean-Congo haemorrhagic fever during the COVID-19 pandemic in Africa: Efforts, recommendations and challenges at hand
    Editorial

    Greene, L.; Uwishema, O.; Nicholas, A.; Kapoor, A.; Berjaoui, C.; Adamolekun, E.; Khoury, C.; Mohammed, F. E. A.; Onyeaka, H.
    African Journal of Emergency Medicine (2022)

    Fulltext@MSK | Save
  • Health-related quality of life of patients with locally advanced or metastatic urothelial cancer treated with enfortumab vedotin after platinum and PD-1/PD-L1 inhibitor therapy: Results from cohort 1 of the phase 2 EV-201 clinical trial
    Journal Article

    McGregor, B.; O'Donnell, P. H.; Balar, A.; Petrylak, D.; Rosenberg, J.; Yu, E. Y.; Quinn, D. I.; Heath, E. I.; Campbell, M.; Hepp, Z.; more...
    European Urology (2022)

    Fulltext@MSK | Save
  • Abemaciclib in combination with endocrine therapy for patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A phase 1b study
    Journal Article

    Tolaney, S. M.; Beeram, M.; Beck, J. T.; Conlin, A.; Dees, E. C.; Puhalla, S. L.; Rexer, B. N.; Burris, H. A. 3rd; Jhaveri, K.; Helsten, T.; more...
    Frontiers in Oncology (2022)

    Fulltext@MSK | Save
  • Evaluating treatment tolerability using the toxicity index with patient-reported outcomes data
    Journal Article

    Langlais, B.; Mazza, G. L.; Thanarajasingam, G.; Rogak, L. J.; Ginos, B.; Heon, N.; Scher, H. I.; Schwab, G.; Ganz, P. A.; Basch, E.; more...
    Journal of Pain and Symptom Management (2022)

    Fulltext@MSK | Save
  • Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: Survival update and new extension cohort data
    Journal Article

    Sehn, L. H.; Hertzberg, M.; Opat, S.; Herrera, A. F.; Assouline, S.; Flowers, C. R.; Kim, T. M.; McMillan, A.; Ozcan, M.; Safar, V.; more...
    Blood Advances (2022)

    Fulltext@MSK | Save
  • Phase I/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring
    Journal Article

    Stewart, C. M.; Michaud, L.; Whiting, K.; Nakajima, R.; Nichols, C.; De Frank, S.; Hamlin, P. A. Jr; Matasar, M. J.; Gerecitano, J. F.; Drullinsky, P.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Multicenter randomized phase II trial of atezolizumab with or without cobimetinib in biliary tract cancers
    Journal Article

    Yarchoan, M.; Cope, L.; Ruggieri, A. N.; Anders, R. A.; Noonan, A. M.; Goff, L. W.; Goyal, L.; Lacy, J.; Li, D.; Patel, A. K.; more...
    Journal of Clinical Investigation (2021)

    Fulltext@MSK | Save
  • Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial
    Journal Article

    Parikh, A. R.; Szabolcs, A.; Allen, J. N.; Clark, J. W.; Wo, J. Y.; Raabe, M.; Thel, H.; Hoyos, D.; Mehta, A.; Arshad, S.; more...
    Nature Cancer (2021)

    Fulltext@MSK | Save
  • Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): A multicenter, two-cohort, non-randomized phase II trial
    Journal Article

    Pascual, T.; Oliveira, M.; Villagrasa, P.; Ortega, V.; Paré, L.; Bermejo, B.; Morales, S.; Amillano, K.; López, R.; Galván, P.; more...
    npj Breast Cancer (2021)

    Fulltext@MSK | Save